The use of a new topical combination drug (metronidazole + chloramphenicol + natamycin + hydrocortisone acetate) for the treatment of vaginitides of various etiologies
- Authors: Apolikhina I.A.1,2, Saidova A.S.1, Kulikov I.A.1,2, Baranov I.I.1
-
Affiliations:
- Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: No 7 (2020)
- Pages: 143-150
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248928
- DOI: https://doi.org/10.18565/aig.2020.7.143-150
- ID: 248928
Cite item
Open Access
Access granted
Abstract
Nonspecific vaginitis (NSV) is an extremely common problem that is of great medical and social importance, especially in the population of women of childbearing age. It seems necessary to study the possibilities of using new topical combination drugs made in Russia for the treatment of NSV, which would not be inferior or superior to foreign analogues in efficiency, safety, and ease of use. Objective. To investigate the efficacy and safety of Targyfort in two parallel groups of 360 women aged 18 to 45 years with a clinical diagnosis of acute vaginitis specified by laboratory assays. The aim was to assess the frequency of complete recovery in the study group at 14 days after treatment completion. The duration of therapy was 10 days in both groups. Subjects and methods. The open-label comparative randomized multicenter clinical trial was conducted in the Russian Federation in 2017-2018. This evaluated the efficacy and safety of Targyfort vaginal suppositories (OAO “Avexima”, Russia) and Tergynan vaginal tablets (Laboratoires Bouchara-Recordati, France) in the treatment of vaginitides of various etiologies. Results. The investigation shows that the efficacy of the Russian drug Targyfort in a number of very important indicators that directly affect quality of life in patients is not lower (no pain (98.3%), burning (97.8%), and itching (98.9%) in the Targyfort group and 98.3, 97.8, and 95.4% in the Tergynan group), whereas the rate of disappearance of the symptoms of pain and burning (4.3 and 4.8 days) is statistically significantly higher than that of Tergynan (5.6 and 5.8 days). Conclusion. The results of the investigation make it possible to recommend Targyfort for the treatment of vaginitides of various etiologies in women of childbearing age as an effective and safe therapeutic drug that is convenient for self-use.
Keywords
Full Text
About the authors
Inna A. Apolikhina
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: apolikhina@inbox.ru
MD, obstetrician&gynecologist, professor
Ayna S. Saidova
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: asekova14@yandex.ru
PhD, obstetrician-gynecologist of the Department of Aesthetic Gynecology and Rehabilitation
Ilya A. Kulikov
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: ginkulikov@yandex.ru
Obstetrician gynecologist
Igor I. Baranov
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: i_baranov@oparina4.ru
MD, PhD, Head of the organizational and methodological department of the scientific and organizational support service
References
- Barbone F., Austin H., Louv W.C., Alexander W.J. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis and bacterial vaginosis. Am. J. Obstet. Gynecol. 1990; 163(2): 510-4. https://dx.doi. org/10.1016/0002-9378(90)91186-g.
- KUkner S., Ergin T., Cigek N., Ugur M., Ye§ilyurt H., Gokmen O. Treatment of vaginitis. Int. J. Gynaecol. Obstet. 1996; 52(1): 43-7. https://dx.doi. org/10.1016/0020-7292(95)02531-6.
- Ozyurt E., Toykuliyeva M.B., Danilyans I.L., Morton O., Baktir G. Efficacy of 7-day treatment with metronidazole + miconazole (Neo-Penotran) - a triple-active pessary for the treatment of single and mixed vaginal infections. Int. J. Gynecol. Obstet. 2001; 74(1): 35-43. https://dx.doi.org/10.1016/s0020-7292(01)00388-5.
- Quan М. Vaginitis: diagnosis and management. Postgrad. Med. 2010; 122(6): 117-27. https://dx.doi.org/10.3810/pgm.2010.11.2229.
- Ефимов Б.А., Тютюнник В.Л. Бактериальный вагиноз: современный взгляд на проблему. РМЖ. 2008; 16(1): 18.
- Кисина В.И., Забиров К.И. Урогенитальные инфекции у женщин. Moscow: МИА; 2005. 276с.
- Carr Ph., Felsenstein D., Friedman R. Evaluation and management of vaginitis. J. Gen. Intern. Med. 1998; 13(5): 335-46. https://dx.doi.org/10.1046/j.1525-1497.1998.00101.x.
- Leitich H., Bodner-Adler B., Brunbauer M., Kaider A., Egarter C., Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am. J. Obstet. Gynecol. 2003; 189(1): 139-47. https://dx.doi.org/10.1067/ mob.2003.339.
- Кира Е.Ф., Гайтукиева Р.А., Беженарь В.Ф., Савичева А.М., Артымук Н.В., Муслимова С.З. Многоцентровое контролируемое рандомизированное сравнительное исследование эффективностии безопасности применения препаратов Полижинакс и Тержинан при лечении неспецифического вагинита. Гинекология. 2009; 11(1): 13-8.
- Додова Е.Г., Аполихина И.А., Горбунова Е.А., Бородина Е.А. Комплексное лечение воспалительных заболеваний нижних отделов генитального тракта у женщин. Акушерство и гинекология. 2015: 6: 129-35.
Supplementary files
